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Chondrosarcoma (CS) is a malignant neoplasm 
with cartilage differentiation. It is the second 
most common primary bone malignancy1,2 and is 
classified on its histological grade for cellularity, 
atypia, and pleomorphism. However, the histo-
logical grading is prone to variations in interpre-
tation.3 This is of importance as CS is resistant 
to radiotherapy and conventional chemotherapy; 
resection, with appropriate margins for the grade 
of tumour, should be the primary goal.2,4-6 What 
constitutes a sufficient margin is debatable. In 
grade 1 CS, intralesional resection with addition 
of adjuvant treatment, such as cementation, is a 
widely accepted treatment.7-10 In true grade 1 CS, 
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Aims
The purpose of this study was to investigate the potential for achieving local and systemic 
control after local recurrence of a chondrosarcoma of bone.
Patients and Methods
A total of 126 patients with local recurrence (LR) of chondrosarcoma (CS) of the pelvis 
or a limb bone were identified from a prospectively maintained database, between 1990 
and 2015 at the Royal Orthopaedic Hospital, Birmingham, United Kingdom. There were 
44 female patients (35%) and 82 male patients (65%) with a mean age at the time of LR 
of 56 years (13 to 96). The 126 patients represented 24.3% of the total number of patients 
with a primary CS (519) who had been treated during this period. Clinical data collected at 
the time of primary tumour and LR included the site (appendicular, extremity, or pelvis); 
primary and LR tumour size (in centimetres); type of operation at the time of primary or 
LR (limb-salvage or amputation); surgical margin achieved at resection of the primary 
tumour and the LR; grade of the primary tumour and the LR; gender; age; and oncological 
outcomes, including local recurrence-free survival and disease-specific survival. A 
minimum two years’ follow-up and complete histopathology records were available for all 
patients included in the study.
Results
For patients without metastases prior to or at the time of local recurrence, the disease-
specific survival after local recurrence was 62.5% and 45.5% at one and five years, 
respectively. After univariable analysis, significant factors predicting disease-specific 
survival were grade (p < 0.001) and surgical margin (p = 0.044). After multivariable analysis, 
grade, increasing age at the time of diagnosis of local recurrence, and a greater time 
interval from primary surgery to local recurrence were significant factors for disease-
specific survival. A secondary local recurrence was seen in 26% of patients. Wide margins 
were a good predictor of local recurrence-free survival for subsequent recurrences after 
univariable analysis when compared with intralesional margins (p = 0.002) but marginal 
margins did not reach statistical significance when compared with intralesional margins  
(p = 0.084).
Conclusion
In cases of local recurrence of a chondrosarcoma of bone, we have shown that if the 
tumour is non-metastatic at re-staging, an increase in disease-specific survival and in local 
recurrence-free survival is achievable, but only by resection of the local recurrence with a 
wide margin.
Cite this article: Bone Joint J 2019;101-B:266–271.
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Table I. Patient characteristics
Patient characteristics n (%)
Eligible patients 126 (100)
Gender
Male 82 (65)
Female 44 (35)
Location
Pelvis 54 (43)
Extremity 69 (55)
Appendicular 2 (2)
Grade of the local recurrence
Grade 1 11 (9)
Grade 2 35 (28)
Grade 3 16 (13)
Dedifferentiated 19 (15)
No histology 17 (14)
Not applicable 28 (22)
Increase in grade from primary to local recurrence 18 (23)
Surgical treatment for local recurrence
No surgery 40 (32)
Limb salvage 63 (50)
Amputation/hindquarter 23 (18)
Margin in local recurrence surgery
Wide 21 (17)
Marginal 34 (27)
Intralesional 7 (4)
No surgery 40 (32)
Not reported 14 (11)
Second local recurrence 32/86 (37)
Metastasis prior or at the time of local recurrence 44/126 (35)
Grade 1 0/27 (0)
Grade 2 22/47 (47)
Grade 3 11/29 (38)
Dedifferentiated 11/23 (48)
Patients with metastases during the study time 69 (55)
Mean time from primary operation to local recurrence, mths 28 (2 to 237)
Mean time from first to second local recurrence, mths 33 (0 to 208)
Mean age at the time of local recurrence, yrs 56 (13 to 96)
intralesional curettage gives good local and systemic control, 
but this is reliant on accurately differentiating grade 1 CS from 
grade 2 CS preoperatively, as intralesional curettage is not an 
acceptable treatment for grade 2 CS, due to the high rate of local 
recurrence (LR) and a decreased survival after LR.11
Misdiagnosing the grade may lead to an underestimation 
of the required margin and thereby increase the risk of LR. In 
true grade 1 CS, LR has a low impact on survival. We have 
previously shown that in grade 2 and 3 CS, LR significantly 
decreased the disease-specific survival (DSS) in competing 
risk analysis, where synchronous metastases (metastases devel-
oped before LR, at the time of LR, or within 90 days after LR) 
and death due to other causes were considered to be compet-
ing events in analyses of the role of LR in DSS.11 High-grade 
tumours are easier to diagnose and the best surgical strategy is 
clearly defined.11,12
Wide surgical excision minimizes the possibility of LR, 
but is often mutilating and sometimes, depending on the loca-
tion of the tumour, impossible to achieve. A positive margin 
is a well-documented risk for LR in CS, but in higher grades 
the definition for an acceptable wide margin remains a matter 
for debate. We have previously shown that surgeons should 
aim for a 4 mm margin to reduce the risk of LR in high 
grade CS.11
The purpose of the current study was to investigate the effect 
of surgical treatment of locally recurrent chondrosarcoma on 
local recurrence-free survival (LRFS) and DSS.
Patients and Methods
This retrospective study included 126 patients, identified from 
a prospectively maintained database, who had been diag-
nosed with LR of a chondrosarcoma of the pelvis or a limb 
bone between 1990 and 2015 at the Royal Orthopaedic Hos-
pital, Birmingham, United Kingdom. There were 44 female 
patients (35%) and 82 male patients (65%) with a mean age 
at the time of LR of 56 years (13 to 96). The 126 patients rep-
resented 24.3% of the total number of patients with a primary 
CS (519) who had been treated during this time. All patients 
were diagnosed and treated at the Royal Orthopaedic Hospital. 
Those who were primarily treated elsewhere and referred for 
the management of a recurrence were excluded. Details of the 
clinical data collected at the time of primary tumour and LR 
included the site (appendicular, extremity, or pelvis); primary 
and LR tumour size (in centimetres); type of operation at the 
time of primary or LR (limb-salvage or amputation); surgical 
margin achieved at resection of the primary tumour and the 
LR; grade of the primary tumour and the LR; gender; age; and 
oncological outcomes, including LRFS and DSS. A minimum 
two years’ follow-up and complete histopathology records were 
available for all patients included in the study. Resection and 
LR specimens were examined by specialized bone sarcoma 
pathologists, for grade and involvement of margins. The high-
est grade seen on histology was the grade recorded, even when 
this higher grade consisted of only a small number of cells. The 
margin was quantified by a specialist bone sarcoma pathologist 
and classified according to the system described by Enneking 
et al.13 Histological biopsies or specimens were not re-reviewed 
but the original report was respected.
Statistical analysis. Descriptive statistics were used to describe 
demographic data. The Kaplan–Meier method was used to 
determine LRFS and DSS. Survival rates were calculated from 
the date of LR to the most recent follow-up, confirmation of 
a second LR, or death. A Kruskal–Wallis test was used for 
statistical analysis of means between the groups. Univariable 
analysis was performed by comparing groups with log-rank test 
with subsequent multivariable Cox proportional hazard analysis 
of significant variables to identify predictors of LRFS and DSS. A 
p-value < 0.05 was considered significant. All statistical analysis 
was completed using SPSS Statistics 24.0 (IBM Corp., Armonk, 
New York).
Results
Clinical features. The mean age for patients with synchronous 
metastases at the time of LR was 61 years (21 to 88). For those 
without metastases at the time of LR, the mean age was 53 years 
(13 to 84) (p = 0.004). The mean time from primary surgery to 
LR was 28 months (2 to 237). The mean follow-up after LR was 
45 months (0 to 256). Patient characteristics are summarized in 
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Fig. 1
Disease-specific survival after local recurrence stratified by metastases 
(mets) prior to or at the time of local recurrence.
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Fig. 2
Disease-specific survival after local recurrence stratified by surgery for 
local recurrence in patients with metastases.
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Fig. 3
Local recurrence-free survival stratified by margin.
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Table I. The most common sites of the primary tumour were 
the proximal femur in 28 patients (22.2%), the acetabulum in 
24 patients (19.0%), the ilium in 16 patients (12.7%), the dis-
tal femur in 15 patients (11.9%), the scapula in eight patients 
(6.3%), the finger and proximal tibia in six patients (4.8%), the 
hemipelvis and pubic bone in five patients (4.0%), the proximal 
humerus in four patients (3.2%), the sacrum and ischial bone 
in three patients (2.4%), the proximal fibula in two patients 
(1.6%), and the distal tibia in one patient (0.8%).
Altogether, 44 of the 126 patients (35%) had metastases prior 
to, or at the time of LR. Metastasis was a significant negative 
factor for survival. Survival for patients with metastases prior 
to, or at the time of, LR was 43.7% at one year and 6.9% at five 
years: 50.0% of patients died within eight months of developing 
metastases (Fig. 1). Surgical treatment of LR among patients 
with metastases at the time of or prior to LR does not improve 
survival (p = 0.218) (Fig. 2).
The histological grade of the LR was available for 81 patients 
(64%). In 18 of these 81 patients (22%), the grade of LR had 
increased from the original resection specimen. Of 18 grade 1 
primary tumours, eight had increased to grade 2 in the LR spec-
imen, three had increased to grade 3, and one had increased to 
a dedifferentiated (DD) CS. Of 33 grade 2 primary CS, five had 
increased to grade 3 in the LR specimen and two had increased 
into DD CS. The grade of LR remained the same in all grade 3 
and DD CS. In grade 1 CS primary tumours treated by intrale-
sional curettage, the increase in grade did not have an impact on 
overall survival (p = 0.238).
Of the 126 patients, 40 patients (32%) did not undergo sur-
gery for their LR. In most, due to the presence of metastatic dis-
ease prior to, or at the time of, LR, 28 of the 126 patients (22%) 
underwent amputation (including hindquarter amputation). Of 
the 126 patients, 58 patients (46%) had limb salvage or local 
resection of the LR at the site of a previous amputation. Mar-
gin (p = 0.251), DSS (p = 0.091), and LRFS (p = 0.117) were 
unaffected by the method of surgical management of the LR 
in terms of limb salvage or limb sacrifice. Surgical margin of 
the LR resection specimen was recorded in 72 patients (83.7%) 
and was intralesional in 17 patients (23.6%), marginal in 34 
patients (47.2%) and wide in 21 patients (29.2%). A second LR 
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Fig. 4
 Disease-specific survival after local recurrence stratified by grade.
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Fig. 5
Disease-specific survival after local recurrence stratified by margin.
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Table II. Results from univariable analysis for disease-specific survival in 
patients without metastases prior to, or at the time of, local recurrence
Variable p-value*
Second local recurrence 0.606
Wide margin 0.044
Metastases < 0.001
Grade < 0.001
Gender 0.136
Location (pelvic vs extremity) 0.456
Increase of grade in local recurrence 0.584
*Kaplan–Meier analysis
Table III. Predictors in multivariate analysis for disease-specific survival 
in patients without metastases prior to, or at the time of, local recurrence
Hazard 
ratio
95% confidence 
interval
p-value*
Dedifferentiated CS 1  
Grade 1 CS 0.003 0.000 to 0.050 0.000
Grade 2 CS 0.018 0.002 to 0.205 0.006
Grade 3 CS 0.23 0.002 to 0.299 0.004
Age at the time of surgery, per year 1.028 1.005 to 1.051 0.018
Time to LR in months, per month 0.942 0.891 to 0.995 0.034
Progression in grade of LR 0.757 0.276 to 2.072 0.587
Location (extremity vs pelvis) 0.710 0.368 to 1.370 0.307
*Cox regression analysis
CS, chondrosarcoma; LR, local recurrencewas seen in 32 patients (37.2%). The mean time from the first 
LR to subsequent LR was 33 months (1 to 208). LRFS for the 
second LR (LRFS) was 65.7% at five years and 42.6% at ten 
years. A wide margin was a good predictor in LRFS for second 
LR in univariable analysis when compared with intralesional 
margin (p = 0.002) but marginal margin did not reach statis-
tical significance when compared with intralesional margin 
(p = 0.084) (Fig. 3).
Overall, DSS after LR was 42.1% at five years and 31.2% 
at ten years. For patients without metastases prior to, or at 
the time of, LR it was 62.5% and 45.5%, respectively (Fig. 
1). In patients without metastases prior to, or at the time of, 
LR, significant factors affecting DSS after univariable anal-
ysis were grade (p < 0.001) (Fig. 4), wide margin compared 
with intralesional margin (p = 0.044), wide margin compared 
with marginal margin (p = 0.026), and marginal margin com-
pared with intralesional margin (p = 0.046) in resection of the 
LR (Fig. 5). After multivariable analysis, grade, age at diag-
nosis of LR, and time from index surgery to LR were signifi-
cant factors for DSS. These results are summarized in Tables II 
and III. 
Discussion
Recurrence of CS, whether in the form of local or metastatic 
disease, adversely affects survival. The aim of treatment of a 
primary CS is to avoid LR, but in cases of LR, we have shown 
that for patients without metastases at the time of LR, resection 
of recurrent disease with wide margins improves both DSS and 
LRFS, when compared with marginal or intralesional margins. 
Further surgery may lead to additional morbidity and a higher 
rate of amputation. Although amputation as a method of treat-
ment of the primary tumour itself does not increase control of 
systemic or local disease,11 large resections and reconstructions 
in the primary operation may reduce the possibility of further 
limb salvage surgery, thereby increasing the risk of higher 
amputation or hind-/forequarter amputation.
The definition of wide margin in Enneking’s classification 
system refers to removing the involved part of the bone with 
a cuff of normal tissue. The metric definition of an acceptable 
margin has never been accurately defined. The incidence of 
wide resection margins in our study was considerably lower 
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than that reported in the literature, being only 29% when com-
pared with 76% in the study from Streitbuerger et al.14 How-
ever, the survival rates were almost identical, which highlights 
the difficulty and the discrepancy that exists in defining what 
constitutes a wide margin or, more importantly, an adequate 
margin to reduce the risk of LR.14
The DSS after LR for all patients was 42.1% at five years 
and 31.2% at ten years. For patients without metastases prior 
to, or at the time of, LR, the DSS was 62.5% and 45.5% at 
five and ten years, respectively. Survival rates are slightly lower 
than in some studies in the literature,15,16 but in agreement with 
other studies.14,17 In line with current studies in the literature, 
tumour grade was the most important prognostic factor for 
patient survival in LRs.6,12,13,18,19 We found that LR of grade 1 
CS was associated with a substantially worse DSS only if the 
grade of LR had progressed. The difference was not statistically 
significant, although this may be compounded by the rarity of 
the event. The role of progression of grade in LR has long been 
debated.17,20-22 We have previously shown that the grade of CS 
should be defined by the highest grade seen in the specimen 
regardless of how small the area of involvement.12 We would 
speculate that higher grade areas seen in the LR are reflective 
of the difficulty of grading the primary tumour, as small areas 
of higher grade may be overlooked when analyzing the primary 
specimen. 
The development of metastasis is a poor prognostic indica-
tor; 50% of patients with metastases prior to, or at the time of, 
LR died within eight months, with most of the rest succumb-
ing to the disease within five years, irrespective of the grade. 
Despite the potential bias towards more aggressive treatment 
for patients without disseminated disease, surgery for LR in 
patients with metastases prior to, or at the time of, LR did not 
give any statistically significant survival advantage. We would 
therefore advocate that aggressive mutilating surgery should 
not be offered to patients in the presence of metastatic disease, 
unless this is within the context of a palliative approach. The 
role of metastasectomy for patients with resectable metastases 
and LR was not investigated in this study but may be consid-
ered on a case-by-case basis. However, the development of 
metastatic disease with LR is suggestive of a more aggressive 
form of the disease and so caution should be exercised as to the 
achievement of cure with combined resection.
Primary pelvic CS is notoriously difficult to treat; treatment 
has a worse outcome than that of extremity CS.1,18 In accordance 
with current literature, our results show that late age at onset 
and shorter disease-free interval are additional factors which 
adversely affect the outcome after LR.17 Therefore, the early 
and accurate detection of LR by frequent follow-up with local 
imaging is of paramount importance. Whether the frequency 
and modality of this follow-up should be tailored on an indi-
vidual patient basis based on the grade, site, size, and margin 
remains an area of debate. In the absence of such data, regular 
surveillance in line with national and international guidelines 
should be advocated.
This study has a number of limitations. First, it is a retro-
spective study compiled from a prospectively maintained data-
base from a single hospital. Second, margin determinations 
were recorded from pathology reports rather than re-analyzing 
each specimen. Therefore, the data relating to margin is prone 
to sampling error not only of the margin but also of the grade of 
the tumour at resection.
In conclusion, aggressive surgical resection with wide mar-
gins remains the cornerstone for achieving disease control in 
patients with locally recurrent CS without metastatic disease, to 
ensure long-term systemic and local DSS.
Take home message
- The development of local recurrence (LR) in chondrosarco-
ma (CS) has a detrimental effect on overall survival, although 
this is affected by the grade of the original tumour and the 
grade of the LR.
- Surgery for patients with LR of CS who have previously developed me-
tastases or develop them at the time of the recurrence does not improve 
overall survival.
- Resection of recurrent disease improves overall survival and disease- 
specific survival in patients without metastatic disease, only when resection 
achieves a wide margin.
Twitter
Follow M. K. Laitinen @MinnaLaitinen2
Follow the authors @ROHOncology
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